Program

During this conference we aim to cover the latest developments in HS research. Submission of new data, ideas and collaborative project proposals is encouraged especially by young researchers from academia, but also from the industry.

Main topics

  • Epidemiology and Registries
  • Clinical classification and outcome measures
  • Medical and Surgical Treatment
  • Genetics
  • Immunology
  • Microbiology
  • Innovative Research

Key note speakers during this conference:

Prof-Gregor-Jemec-rond

Prof. Gregor Jemec
Department of Dermatology
University of Copenhagen
Roskilde Hospital
Roskilde, Denmark

Prof-Christos-Zouboulis-rond

Prof. Christos Zouboulis
Städtisches Klinikums Dessau
Dessau, Germany

Prof-Jonathan-Barker-rond

Prof. Jonathan Barker
St John’s Institute of Dermatology
King’s College
London, UK 

Prof-Herve-Bachelez-rond

Prof. Hervé Bachelez
Department of Dermatology
Saint-Louis Hospital
Paris, France

Sabine-Duchatelet

Dr. Sabine Duchatelet
Department of Genetics
Necker hospital for sick children
University Paris Descartes – Sorbonne
Paris, France

AndreDaCosta-rond2

Andre da Costa
UCB BioPharma SPRL,
Belgium

UCB
Frank_Van_de_Veerdonk-rond

Dr. Frank van de Veerdonk
Institute for Infection
Inflammation and Immunity (N4i)
Radboud University
Nijmegen The Netherlands

Radboud-University-Nijmegen-logo
WEDNESDAY FEBRUARY 7th
16.30 – 18.00 Registration
18.00 – 18.10 Official welcome by conference president E. Prens (NL)
18:10 – 18:40 The genetics of hidradenitis suppurativa and associated syndromic forms S. Duchatelet (FR)
18:40 – 19:10 The process of PROM development in HS G. Jemec (DK)
19:10 – 19:40 Hidradenitis immunopathogenesis, lessons learned from psoriasis J. Barker (UK)
19:40 – 21:30 Welcome Reception and Networking evening
THURSDAY FEBRUARY 8th
07:30 – 08.30 Registration
08.30 – 09.00 EHSF e.V. General Assembly
09.00 – 09.50 Outcome measures (Chairs G. Jemec & W. Gulliver)
09:02 – 09:12 Factors associated with patient-reported measures in patients with Hidradenitis Suppurativa B. Calimlim (US)
09:14 – 09:24 International Hidradenitis Suppurativa Severity Score System (IHS4): a validated dynamic scoring system and future perspectives T. Tzellos (NO)
09:26 – 09:36 Patient reported quality of life within refined Hurley stages for hidradenitis suppurativa A. Rondags (NL)
09:38 – 09:48 Which factors influence deterioration of the quality of life in HS patients? P. Guillem (FR)
09:50 – 10:20 HISTORIC G. Jemec (DK)
10:20 – 10:40 Coffee break
10:40 – 11:20 Immunology (Chairs E. Giamarellos – Bourboulis & E. Prens)
10:42 – 11:52 Biologic susceptibility of HS lesional skin: an ex vivo study A. Vossen (NL)
10:54 – 11:04 Patients with hidradenitis suppurativa have abnormalities in circulating B cell subsets J.Musilova (IR)
11:06 – 11:16 Upregulation of SERPINB3/B4 and S100A7-9 in hidradenitis suppurativa/acne inversa A. Aljowder (DE)
11:20 – 11:50 Molecular taxonomy of diseases: an opportunity to improve Hidradenitis Suppurativa diagnosis and therapy A. Da Costa (BE)
11:50 – 13:00 Lunch break
13:00 – 13:50 Epidemiology and clinical classification
13:02 – 13:12 European Registry for Hidradenitis Suppurativa (ERHS): A single center experience M. Daxhelet (BE)
13:14 – 13:24 Hidradenitis Suppurativa – an international survey of Children, by the Faster and Better Group P. Riis (DK)
13:26 – 13:36 HS disease progression from onset to Hurley stage III A. Vanlaerhoven (NL)
13:38 – 13:48 Hidradenitis suppurativa of the posterior neck: description of an atypical phenotype related to severe, early onset disease in males J. Romani de Gabriel (ES)
13:50 – 17:05 Medical treatment
13:52 – 14:02 An open-label extention study (OLE) of MABP1 targeting interleukin-1alpha for hidradenitis suppurativa (HS) E. Giamarellos (GR)
14:04 – 14:14 Assessment of Adalimumab efficacy among adult patients suffering from hidradenitis suppurativa and identification of predictive factors for the therapeutic response: Evidence from the Belgian cohort F. Benhadou (BE)
14:16 – 14:26 Comparison of disease status and outcomes of hidradenitis suppurativa patients experienced with biologics or biologics naive in Europe Y. Lu (UK)
14:28 – 14:38 Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab E. Giamarellos (GR)
14:40 – 14:50 Acne flare on isotretinoin; a clue to the diagnostic of hidradenitis suppurativa J. Revuz (FR)
14:52 – 15:02 Defining fistular structures in Hidradenitis suppurativa: impact in the management A. Martorell (ES)
15:05 – 15:35 Coffee break and poster walk (‘van Beuningen zaal’ and ‘Schadee zaal’)
15:35 – 16:05 The bacteriology of HS  C. Zouboulis (DE)
16:05 – 16:45 Microbiology
16.07 – 16:17 Identification of Bacterial DNA in the Peripheral Blood of Patients With Active Hidradenitis Suppurativa J. Pascual (ES)
16:19 – 16:29 Antibiotic Therapy and Antibiotic Resistance in Hidradenitis Suppurativa: Lessons from Microbiology V. Bettoli (IT)
16:31 – 16:41 The microbiome in sinus tracts of hidradenitis suppurativa patients H. Ring (DK)
18:30 – 22:30 Conference diner (Boarding time bus: 18:00 – 18:30 from registration desk entrance)
FRIDAY FEBRUARY 9th
08:00 – 09:00 Registration
09:00 – 09:40 Genetics
09:02 – 09:12 Metastatic anal squamous cell carcinoma in a 31-year old patient with hidradenitis suppurativa Hurley stage III. A case report G. Nikolakis (DE)
09:14 – 09:24 Molecular characterization of hidradenitis suppurativa/acne inversa (HS) C. Zouboulis (DE)
09:26 – 09:36 Gamma-secretase gene mutation analysis in Hidradenitis Suppurativa and acne conglobata: evidence of genetic heterogeneity and novel NCSTN gene mutation B. Gorijala (IN)
09:40 – 10:10 Functional immunogenetics of familial HS F. van de Veerdonk (NL)
10:10 – 10:40 Aspects of neutrophilic inflammation in HS H. Bachelez (FR)
10:40 – 11:10 Coffee break
11:10 – 12:40  AbbVie symposium – Modifying the HS patient journey: what can we do today?
11:10 – 11:20 Welcome F. Bechara (DE)
11:20 – 11:40 Delayed diagnosis and treatment: What is the clinical and emotional impact on the patient journey T. Tzellos (NO)
11:40 – 12:00 Changing the course: The importance of early assessment and modification of patients’disease A. Martorell (ES)
12:00 – 12:25 Establishing multidisciplinary management strategies for each and every one of our patients F. Bechara (DE)
12:25 – 12:40 Q&A: How can we modify the patient journey in clinical practice F. Bechara (DE)
12:40 – 12:40 Meeting close F. Bechara (DE)
12:40 – 13:30  Lunch break
13:30 – 14:30 Surgical treatment and innovative research
13:32 – 13:42 Long-wave Infra-Red Thermography (IRT): an objective technique of detection and assessment of inflammation in hidradenitis suppurativa/acne inversa (HS) C. Zouboulis (DE)
13:44 – 13:54 Quality of life effects in patients treated with the Laight®–Therapy U. Kirschner (DE)
13:56 – 14:06 Adalimumab in Conjunction with Surgery in Patients with Moderate to Severe Hidradenitis Suppurativa: Study Design and Baseline Results from a Phase 4, Double-Blind, Randomized, Placebo-
Controlled Study
F. Bechara (DE)
14:08 – 14:18 Surgery for hidradenitis suppurativa: the Belgian algorithm M. Suppa (BE)
14:20 – 14:28 Efficacy and safety of CO2 laser for the treatment of hidradenitis suppurativa Ø. Grimstad (NO)
14:30 – 14:40 Patient Association (EFPO) G. Pintori & B. Villumsen
14:40 – 15:10 Coffee break and poster walk (‘van Beuningen zaal’ and ‘Schadee zaal’)
15:10 – 16:00 Comorbities and endocrinology
15:12 – 15:22 BMI at the onset of hidradenitis suppurativa K. van Straalen (NL)
15:24 – 15:34 Cutaneous Signs of Insulin Resistance in Hidradenitis Suppurativa C. Gallagher (IR)
15:36 – 15:46 Evaluation of cigarette dependence in HS patients P. Guillem (FR)
15:48 – 15:58 High prevalence of axial and peripheral spondyloarthritis features in patients with hidradenitis suppurativa: a cross-sectional study A. Rondags (NL)
16:00 – 16:15 Poster award and closing ceremony

Poster Presentations

01 Serum zinc levels in hidradenitis suppurativa. A case control study J. Pascual
02 Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients with Moderate or Severe Hidradenitis Suppurativa on Adalimumab Treatment (HOPE study), interim analysis L. Emtestam
03 Epidemiology, clinical characteristics and comorbidities of Hidradenitis Suppurativa in Tuscany: A tale of 290 patients F. Prignano
04 Comparative study between patients with hidradenitis suppurativa vs patients with psoriasis: psychological impact E. de Miguel
05 Association of polymorphisms in the MyD88 gene and susceptibility to severe Hidradenitis suppurativa in a Caucasian population of 101 patients E. Agut-Busquet
06 Quantitative infrared thermography in hidradenitis suppurativa: a pilot study F. Benhadou
07 Role of Staphylococcus lugdunensis in hidradenitis suppurativa G. Martin-Ezquerra
08 Crystal deposition in Hidradenitis Suppurativa J. Pascual
09 Alexithymia affects patients with hidradenitis suppurativa A. Chiricozzi
10 Power Doppler ultrasound assessment of vascularization in hidradenitis suppurativa lesions R. Caposiena Caro
11 How to optimize neurosurgical approach decision in case of inflammatory hidradenitis suppurativa lesions involving the lumbo-sacral area : Report of a clinical case F.Benhadou
12 Change of the IHS4 score as measure of long-term adalimumab efficacy in hidradenitis suppurativa (HS): a real life cohort E. Giamarellos
13 Validation of the IHS4 score as an outcome measure for hidradenitis suppurativa (HS): application in treatment with MABP1 targeting interleukin 1-alpha E. Giamarellos
14 Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents H. Tiri
15 Standardised clinical documentation of hidradenitis suppurativa/acne inversa (HS) C. Zouboulis
16 Paradoxical reaction to anti-TNF treatment in a patient with HS and psoriasis W. Gulliver
17 Study of human papillomavirus presence in gluteal lesions and in squamous cell carcinoma complicating hidradenitis suppurativa C. Hotz
18 Hidradenitis suppurativa and genetic predisposition V.Tzanetakou
19 Secondary prevention of Hidradenitis suppurativa in daily practice H.Kurzen
20 Descriptive analysis of patients with suppurativa hidradenitis with a family history of the disease R.Diaz Diaz
21 Patient benefit index for hidradenitis suppurativa – a new Instrument to assess Patient related outcomes N. Kirsten
22 Epidemiology of hidradenitis suppurativa in Germany – a multisource approach N. Kirsten
23 The Danish National Process as part of the Development of HISQoL – an international Hidradenitis Suppurativa specific Quality of Life Instrument S. Esmann
24 European Registry for Hidradenitis Suppurativa (ERHS): state of play 2017 M. Daxhelet
25 Comorbidities or different entities phenotype variability associated with PSENEN gene mutations C. Li
26 A pilot study of Quality of Pain in patients with Hidradenitis Suppurativa V. Sigsgaard
27 A pilot study of Body Image in patients with Hidradenitis Suppurativa P. Sorensen
28 Severe hidradenitis suppurativa in patients over 70-year-old with good response to treatment with adalimumab C. Ciudad Blanco
29 Hidradenitis suppurativa and pyoderma gangrenosum, experience from the Bulgarian expert center of HS E. Hristakieva
30 Prevalence of Hidradenitis suppurativa in a cohort of Danish Blood Donors P. Riis
31 Socioeconomics of blood donors screened positive for Hidradenitis Suppurativa P. Riis
32 The symptom self-assessment of patients with hidradenitis suppurativa according to the refined Hurley classification A. Rondags
33 Obstructive Sleep Apnea in Hidradenitis Suppurativa A. Kelly
34 Effectiveness and safety of intralesional triamcinolone in the management of patients with hidradenitis suppurativa: a case series study A. Molina-Leyva
35 Hidradenitis suppurativa and thrombophilia: is there an association or do they just coexist? V. Tzanetakou
36 Could Isotretionoin (Roacutane) flare hidradenitis suppurativa? C. Gallagher
37 Concealed emotions: alexithymia in hidradenitis suppurativa P. Guillem
38 When does acne stop and Hidradenitis suppurativa begin?” C. Gallagher
39 Obesity significantly influences HS phenotype and severity P. Guillem
40 Cigarette smoking significantly influences HS phenotype and severity P. Guillem
41 Lipoprotein Analysis in Hidradenitis Suppurativa S. Jeyarajah
42 Sex-specific differences in patients with hidradenitis suppurativa S. Schneider-Burrus
43 The role of dietary factors in hidradenitis suppurativa: preliminary results from an observational study S. Garcovich
44 Evaluation of cannabis use in HS patients P. Guillem
45 Poor inter-rater reliability of hidradenitis suppurativa phenotypes by Canoui-Poitrine et al H. van der Zee
46 Hidradenitis suppurativa, which treatment is better: doxycycline or a combination of clindamycin and rifampicin? N. Kappe
47 Effectiveness of intralesional photodynamic therapy in the management of Hidradenitis Suppurativa? M. Valladares
48 PASH syndrome, dermatitis herpetiformis Duhring and recurrent erythema nodosum S. Valiukeviciene
49 Herbal Medicine Today: Clinical and Research M. al Bassir Rahamani